| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 1997;96:1305-1312.)
© 1997 American Heart Association, Inc.
Articles |
From the Heart Institute, Hospital of the Good Samaritan, and Department of Medicine, Section of Cardiology, University of Southern California, Los Angeles.
Correspondence to Karin Przyklenk, PhD, Heart Institute/Research, Good Samaritan Hospital, 1225 Wilshire Blvd, Los Angeles, CA 90017.
| Abstract |
|---|
|
|
|---|
Methods and Results To test this hypothesis, anesthetized dogs received a 15-minute intracoronary infusion of 20 mmol/L CaCl2 or saline before undergoing 1 hour of coronary occlusion and 4 hours of reperfusion (protocol 1). Collateral blood flow during occlusion was measured with radiolabeled microspheres, area at risk of infarction (AR) was delineated by injection of blue dye, and area of necrosis (AN) was determined by tetrazolium staining. AN/AR was reduced from 20±5% in the saline-treated controls to 9±3% in CaCl2-treated dogs (P<.05). Additional animals underwent 10 minutes of preconditioning ischemia or a comparable waiting period before the 1-hour test occlusion (protocol 2). Administration of 5-(N,N-dimethyl)-amiloride (an inhibitor of calcium influx via Na+-H+ and Na+-Ca2+ exchange) before the preconditioning stimulus attenuated the protective effect of ischemic preconditioning: AN/AR was 12±1%, larger than the value of 4±1% observed in preconditioned dogs that received saline (P<.05) and comparable to the values of 12±3% and 14±3% seen in saline- and dimethylamiloride-treated controls.
Conclusions Brief intracoronary infusion of CaCl2 mimicked, whereas treatment with dimethylamiloride blocked, infarct size reduction with preconditioning, thereby implicating calcium as a mediator of preconditioning in this canine model.
Key Words: calcium ischemia myocardial infarction signal transduction
| Introduction |
|---|
|
|
|---|
Regulation of ionic homeostasis, particularly calcium, is a crucial determinant of myocyte viability. Considerable evidence indicates that brief, nonlethal episodes of myocardial ischemia are associated with a brief, transient, and reversible increase in cytosolic calcium concentrations, whereas a massive increase in total calcium content is a hallmark of myocytes irreversibly injured by prolonged ischemia/reperfusion.9 10 11 12 13 14 15 This focal role of calcium led us to postulate that a brief, transient, and modest increase in intracellular calcium concentration during the preconditioning stimulus may be an important component of the second-messenger pathway ultimately responsible for the reduction of infarct size seen with ischemic preconditioning. If so, then brief intracoronary infusion of calcium in lieu of brief ischemia should mimic the protective effects of preconditioning. Moreover, because calcium influx during ischemia/reperfusion occurs at least in part as a secondary consequence of intracellular acidosis and resultant activation of Na+-H+ and Na+-Ca2+ exchange,11 12 13 14 15 we further proposed that the selective Na+-H+ exchange inhibitor DMA,16 administered during the preconditioning stimulus, should attenuate the reduction of infarct size seen with preconditioning. Using the anesthetized canine model, we sought to determine whether calcium may serve as a mediator of infarct size reduction with preconditioning by evaluating each of these two corollaries.
| Methods |
|---|
|
|
|---|
Surgical Preparation
Seventy-four mongrel dogs weighing between 14 and 32 kg were
anesthetized with sodium pentobarbital (30 mg/kg), intubated,
and ventilated with room air. After cannulation of the left jugular
vein (for administration of fluids and supplemental
anesthesia) and the left carotid artery (for measurement of
heart rate and arterial pressure), the heart was exposed
through a left lateral thoracotomy and suspended in a pericardial
cradle. A fluid-filled catheter was positioned in the left atrium for
later injection of radiolabeled microspheres
(141Ce, 103Ru, or 95Nb) for
measurement of RMBF, and a microtipped pressure transducer was
positioned in the LV cavity via the left atrial appendage for
measurement of LV pressure and its first derivative, LV dP/dt. A
segment of the LAD was isolated, usually distal to its first major
diagonal branch, for later placement of occlusive vascular clamps, and
a second segment was isolated for placement of a Doppler flow probe
for measurement of mean CBF.
Protocol 1: Intracoronary Calcium Infusion
In the 28 dogs enrolled into the first limb of the study, a
proximal branch of the LAD was cannulated with a 24-gauge catheter, and
the tip was advanced into the lumen of the main LAD. Each dog was
randomized to receive a 15-minute IC infusion of either
CaCl2 (concentration of 20 mmol/L infused at a rate of
0.5 mL/min, ie, 1.47 mg/min) or saline (0.5 mL/min) into the
soon-to-be-ischemic LAD bed, followed by a 10-minute saline
"washout" at 0.5 mL/min (Fig 1
). This "dose"
was selected, on the basis of work by Ito et al,17 such
that a small but consistent increase in LV dP/dt (suggestive of
a modest increase in intracellular calcium concentration) was obtained
during CaCl2 infusion compared with baseline but with no
significant differences between the saline- and calcium-treated groups.
All dogs then received a prophylactic dose of lidocaine
(
1.5 mg/kg IV bolus) and underwent 1 hour of sustained LAD occlusion
followed by 4 hours of reperfusion. Hemodynamics and
CBF were monitored before and during saline or calcium infusion, before
and throughout sustained LAD occlusion, and after sustained reflow. In
addition, the severity of ischemia was assessed in all dogs by
measurement of RMBF at 30 minutes into the prolonged LAD occlusion.
|
At the end of the protocol, the LAD was ligated at the site of previous occlusion, and Unisperse blue pigment (0.25 to 0.5 mL/kg) was injected into the coronary vasculature via the left atrial catheter to delineate the in vivo extent of the occluded LAD bed, or AR. Under deep anesthesia, cardiac arrest was produced by intracardiac injection of KCl. The hearts were rapidly excised, cut into five to seven transverse slices, and photographed for later measurement of AR. To distinguish necrotic from viable myocardium, the standard method of incubation for 10 minutes in a 1% solution of triphenyltetrazolium chloride at 37°C was used,5 8 and the heart slices were rephotographed for later calculation of the AN and stored in formalin.
Protocol 2: Effect of DMA on Ischemic Preconditioning
Of the 46 animals entered into the second limb of the study, 20
were assigned to undergo one 10-minute episode of preconditioning
ischemia and 30 minutes of reperfusion before the 1-hour
sustained test occlusion (Fig 1
). Immediately before preconditioning,
either DMA (400 µmol/L, n=12) or saline (n=8) was administered
directly into the soon-to-be-ischemic LAD territory via
30
intramyocardial injections (0.15 mL each) into the subendocardium at a
depth of 8 to 10 mm, an approach successfully used by our
laboratory and others to facilitate local drug delivery in the absence
of deleterious and confounding hemodynamic
consequences.5 7 18 The remaining 26 dogs served as
controls and received
30 intramyocardial injections of DMA (n=15) or
saline (n=11) followed by an equivalent 40-minute waiting period before
the 1-hour sustained occlusion. Hemodynamics and CBF
were monitored at frequent intervals throughout the protocol, RMBF was
measured at 30 minutes into the sustained LAD occlusion, and infarct
size was delineated as described in protocol 1.
Exclusion Criteria
Dogs from either protocol were excluded from analysis
according to the following standard prospective criteria: (1) high
collateral blood flow, defined as values of RMBF to the
"ischemic" subendocardium >0.20
mL·min-1·g
tissue-1; (2) a small AR, defined as AR <10%
of the LV; or (3) intractable VF, unresponsive to cardioversion with
low-energy (20- to 30-J) DC pulses applied directly to the heart.
Analysis
AR and infarct size. After fixation, right
ventricular tissue was trimmed from each heart slice, and
the remaining LV tissue was weighed. Photographic images of the heart
slices were projected and traced at magnifications of
x2 to
x4. The extent of the AR and AN in each heart slice was quantified by
computerized planimetry, corrected for the weight of the tissue slice,
and summed for each heart.
Regional myocardial blood flow. After LV weights had been obtained, tissue blocks were cut from the center of the previously ischemic LAD bed and remote, normally perfused circumflex bed and divided into subendocardial, midmyocardial, and subepicardial segments. RMBF was then quantified by the standard method described previously.5 8
Hemodynamics and CBF. Heart rate and arterial pressures were measured and averaged over five continuous cardiac cycles in sinus rhythm for each sample period. Mean CBF was also recorded during these same five cardiac cycles and expressed as a percentage of CBF measured at baseline.
Statistics
Because protocols 1 and 2 were conducted consecutively and not
concurrently, statistical analyses were performed separately
for each limb of the study. In protocol 1, RMBF, risk region, and
infarct size in calcium- and saline-treated animals were compared by
unpaired t tests, and the incidence of VF was compared by
Fisher's exact test. ANCOVA was used to determine whether the
relationship between infarct size and collateral blood flow differed
between the two groups. Hemodynamic
parameters were compared at baseline, at 15 minutes into
CaCl2/saline infusion, before sustained occlusion, at 30
minutes and 1 hour into sustained occlusion, and at 15 minutes, 1 hour,
and 4 hours after reperfusion by two-factor ANOVA (for treatment and
time) with repeated measures across the second factor, and if
significant F ratios were obtained, subsequent pairwise
comparisons were made by Tukey's test. Statistical comparisons for
protocol 2 were done in a similar manner, except discrete variables
(RMBF, risk region, infarct size) were compared by ANOVA followed by
Tukey's test. All data are expressed as mean±SEM, and values of
P<.05 were considered to be statistically
significant.
| Results |
|---|
|
|
|---|
|
Hemodynamics. Baseline values of heart rate,
arterial pressure, and dP/dt were similar in both groups
(Table 2
). Comparison of hemodynamic
parameters measured at the end of the 15-minute IC infusion
with their respective baseline values revealed, as expected, a small
but consistent increase in LV dP/dt in the
CaCl2-treated group (1618±159 versus 1416±139
mm Hg/s, P<.01). There was, however, no significant
difference with saline infusion (1488 versus 1454 mm Hg/s) and no
significant difference between groups. When data obtained throughout
infusion, occlusion, and reperfusion were included in the statistical
analysis, this modest increase in LV dP/dt with
CaCl2 infusion did not achieve significance.
|
Coronary blood flow remained stable at
100% of baseline
throughout IC infusion of calcium or saline. All dogs were
hyperemic upon reperfusion, with CBF remaining comparable
between the groups throughout the 4 hours of reflow.
Regional myocardial blood flow. Collateral blood flow during
sustained LAD occlusion was similar in saline- and calcium-treated
animals: ie, subendocardial RMBF was 0.06±0.02 and 0.05±0.02
mL·min-1·g-1,
respectively (Table 3
). In addition, RMBF measured in
the normally perfused circumflex bed during LAD occlusion did not
differ between groups.
|
Risk region and infarct size. AR tended to be larger in the
calcium-treated group than in the saline controls (23±2% versus
19±1% of the total LV weight, P=.07; Fig 2A
). Nonetheless, infarct size in dogs treated with IC
CaCl2 averaged only 9±3% of the AR (or 2.1% of the total
LV), significantly smaller than the value of 20±5% (or 3.9% of the
total LV) observed in animals that received IC saline
(P<.05; Fig 2A
). This reduction in infarct size with IC
CaCl2 was confirmed by ANCOVA: when collateral blood flow
was incorporated as a covariate, the relationship between AN/AR and
subendocardial RMBF was shifted downward for calcium-treated animals
versus saline controls (P<.03; Fig 2B
).
|
Protocol 2
Mortality and exclusions. Of the 46 dogs entered into
the second limb of the study, 8 received intramyocardial saline and 12
received intramyocardial DMA before 10 minutes of preconditioning
ischemia, and 26 controls (11 treated with saline and 15 with
DMA) received intramyocardial injections before the 40-minute waiting
period (Table 1
). Of the 2 saline-preconditioned, 6 DMA-preconditioned,
8 saline control, and 6 DMA control dogs that developed VF
(P=NS), both saline-preconditioned, 4 DMA-preconditioned, 2
saline control, and 2 DMA control dogs were successfully resuscitated.
Three DMA control dogs were excluded because of high collateral blood
flow, and 1 DMA-preconditioned animal was excluded because of technical
difficulties. Thus, a total of 5 saline control, 8 DMA control, 8
saline-preconditioned, and 9 DMA-preconditioned animals completed the
protocol.
Hemodynamics. Animals assigned to the
DMA-preconditioned group tended to have higher values of heart rate,
mean arterial pressure, and LV dP/dt at baseline (ie,
before randomization), and for both heart rate and arterial
pressures, this trend persisted throughout much of the protocol (Table 2
). However, only two treatment effects attained statistical
significance: heart rate was transiently increased by 16 to 19 bpm with
intramyocardial saline injections (P<.05 for the
saline-preconditioned group), and peak positive dP/dt in the DMA
control cohort increased from 1281 mm Hg/s at baseline to
1500 mm Hg/s immediately before sustained occlusion
(P<.05).
Coronary blood flow increased to
130% of baseline values in
all groups in response to intramyocardial injection of either DMA or
saline. CBF returned to 96% to 101% of baseline in all groups before
the onset of sustained occlusion, and all dogs exhibited
hyperemia upon reperfusion.
Regional myocardial blood flow. Collateral blood flow during
sustained occlusion was similar in all groups, ie, mean subendocardial
RMBF in the LAD bed ranged from 0.02 to 0.05
mL·min-1·g
tissue-1 (Table 3
). RMBF in the normally
perfused circumflex bed was also comparable among the four cohorts.
Risk region and infarct size. AR in the four groups
averaged 18% to 21% of the total LV weight (P=NS; Fig 3A
).
|
Mean infarct size in the saline and DMA control groups was 12±3%
and 14±3% of the AR, respectively (P=NS). As expected,
AN/AR was significantly smaller in the saline-preconditioned group,
averaging only 4±1% (P<.01; Fig 3A
), and ANCOVA revealed
a significant downward shift in the regression relationship between
infarct size and subendocardial collateral blood flow for
saline-preconditioned dogs compared with controls
(P<.05 versus saline controls; P<.02 versus DMA
controls; P<.01 versus all controls; Fig 3B
). In contrast,
infarct size in the DMA-preconditioned cohort was 12±1%,
significantly greater than the value of 4% obtained in
saline-preconditioned animals and comparable to the infarct sizes of
12% and 14% seen in the saline and DMA controls (Fig 3A
). Moreover,
the regression relationship for the DMA-preconditioned group was
shifted upward compared with the saline-preconditioned group
(P<.01; Fig 3B
) and did not differ from that of the
controls (P=.9).
The apparently chance trend of higher heart rates and
arterial pressures in the DMA-preconditioned group raises
the concern that the larger infarct sizes in these animals versus
saline-preconditioned dogs were simply due to higher oxygen demand
during occlusion. Importantly, however, when AN/AR for the DMA- and
saline-preconditioned groups was plotted as a function of
hemodynamic parameters measured midway
during the sustained occlusion, we observed no correlation between
infarct size and heart rate, mean arterial pressure, or
their product (all P
.44; Fig 4
). These
results indicate that the larger infarct sizes obtained in
DMA-preconditioned dogs were due to an attenuation of the
preconditioning effect by DMA.
|
| Discussion |
|---|
|
|
|---|
Brief Transient Calcium Infusion Protects the Heart Against
Subsequent Sustained Ischemia
Our results showing infarct size reduction with brief infusion of
CaCl2 are in agreement with preliminary reports in the dog
model19 20 and recent evidence obtained in isolated
buffer-perfused rat hearts21 : IC infusion of
CaCl219 20 and CaCl2 added to the
perfusate21 limited infarct size caused by
subsequent sustained occlusion and enhanced the acute recovery of
contractile function after relief of ischemia in the two
models, respectively. Because 20 mmol/L CaCl2 produced
only a modest (
200 mm Hg/s) increase in LV dP/dt, our results
indicate that the cardioprotective effects of brief
preischemic administration of calcium are not simply due to
relative demand-induced ischemia during infusion.
DMA Attenuates the Cardioprotective Effects of Ischemic
Preconditioning
The obvious question arising from protocol 1 is, Does the
cardioprotection seen with brief exogenous calcium infusion and
ischemic preconditioning share a common pathway? Considerable
evidence indicates that transient, nonlethal episodes of
ischemia are associated with brief, transient, and reversible
increases in cytosolic calcium concentrations.9 10 12 13 14
Calcium influx during brief ischemia is, at least in part, a
secondary consequence of intracellular acidosis: the increase in
intracellular concentrations of H+ stimulates
Na+-H+ exchange, resulting in the extrusion of
H+, influx of Na+, and subsequent increase in
intracellular calcium via Na+-Ca2+
exchange.11 12 13 15 The importance of this pathway may
diminish during prolonged ischemia, because extrusion of
H+ and resultant extracellular acidosis serve to inhibit
Na+-H+ exchange. However, reperfusion and the
resultant washout of extracellular H+ rapidly
reactivate Na+-H+ exchange, thereby
restoring normal pH at the price of Na+ and subsequent
Ca2+ influx.11 12 13 15
To evaluate the potential role of calcium influx via
Na+-H+ exchange during the preconditioning
stimulus in reduction of infarct size, we administered the selective
Na+-H+ exchange inhibitor
DMA16 22 by direct intramyocardial injection immediately
before 10 minutes of preconditioning ischemia and 30 minutes of
intervening reperfusion. Two aspects of our protocol design warrant
comment. First, our decision to deliver DMA by intramyocardial
injections was based on preliminary experiments in which continuous IC
infusion of DMA appeared to precipitate VF (perhaps because of
inhibited extrusion of H+ and exacerbated acidosis during
brief ischemia/reperfusion), similar to previous observations
with high-dose intracoronary infusion of amiloride in
anesthetized dogs.23 Our laboratory and others
have found intramyocardial injections or microinfusions to be an
effective method to administer inotropic and vasoactive compounds such
as phorbol myristate acetate, adenosine, and PKC
inhibitors5 7 18 directly to the
ischemic/reperfused myocardium in the absence of
confounding systemic hemodynamic effects. It is
important to note, however, that intramyocardial injections per se can
initiate cardioprotection: we have found that direct intramyocardial
injections of saline alone, made immediately before sustained
coronary artery occlusion, significantly limited infarct size
in both the rat and dog models because of local stretch and/or focal
ischemia at the injection sites.18 Indeed, despite
the difference in time course between the two studies (ie, injections
made immediately before versus 40 minutes before sustained
coronary occlusion), a persistent protective effect of the
injections was also observed in the present protocol: mean infarct
size in the saline and DMA controls was 12% to 14%, identical to the
value of 12% obtained previously in the cohort of dogs in which
subendocardial blood flow was <0.20
mL·min-1·g-1
during occlusion18 and smaller than the control values of
20% typically observed in our laboratory (and obtained in
protocol 1) with 1 hour of LAD occlusion in this
model.5 8
A second issue is our choice of 10 minutes of brief preconditioning ischemia followed by 30 minutes of intervening reperfusion. Our objective was to select a preconditioning regimen that, together with our choice of intramyocardial delivery of DMA, would provide a high probability of large interstitial concentrations of DMA being present throughout preconditioning ischemia and upon reperfusion. However, because considerable evidence indicates that amiloride and its analogues are highly cardioprotective if administered during a sustained period of regional or global myocardial ischemia,22 23 24 25 26 we used a prolonged 30-minute period of intervening reflow to facilitate diffusion and dissipation of DMA before the onset of the sustained test occlusion. As expected,27 10 minutes of ischemia plus 30 minutes of reflow was an effective preconditioning stimulus: this was confirmed in initial pilot experiments (ie, infarct size and subendocardial collateral blood flow averaged 5% and 0.02 mL·min-1·g tissue-1 in 3 dogs preconditioned with 10 minutes of ischemia that did not receive saline injections) and supported by the infarct size of 4±1% observed in our saline-preconditioned cohort.
Intramyocardial injections of DMA blocked the protective effects of preconditioning in our model: AN/AR in the DMA-preconditioned group was 12%, significantly larger than the value of 4% obtained in saline-preconditioned dogs and comparable to the infarct sizes of 12% to 14% in the saline and DMA control groups. The fact that infarct size was similar in both control cohorts may be interpreted to suggest that addition of DMA to the injection fluid failed to attenuate the protective effect of the injections per se, thereby implying that the mechanisms responsible for protection by ischemic preconditioning differ from those of local injections. An alternative explanation, however, is that despite the 40-minute interval between injection and the onset of coronary occlusion, residual amounts of DMA were present in the occluded LAD bed at the onset of sustained occlusion and exerted a modest protective effect (approximately equal in magnitude to that achieved by intramyocardial injections) during the prolonged ischemic insult. Although resolution of this latter issue is beyond the scope of this study, the results of protocol 2 nonetheless indicate that DMA abrogated the protection conferred by brief antecedent ischemia/reperfusion.
Comparison With Previous Studies
Several previous studies have sought to document favorable changes
in calcium regulation, manifest after repeated brief ischemia
or during a later test occlusion, in preconditioned hearts versus
controls.28 29 30 31 32 33 In contrast, our specific objective in
protocol 2 was to focus on the possible role of brief transient calcium
influx via Na+-H+ exchange during the
preconditioning stimulus on subsequent infarct size reduction. Our
results differ from the one previous study that also endeavored to
measure infarct size with administration of a
Na+-H+ exchange inhibitor in the
setting of brief preconditioning ischemia. In contrast to our
observations, Bugge and Ytrehus33 found that ethyl
isopropyl amiloride, preconditioning, and the combination of
preconditioning plus the amiloride analogue were equally protective in
an isolated rat heart model of regional ischemia. Moreover,
when the duration of sustained occlusion was prolonged such that the
benefits of preconditioning began to wane, concomitant treatment with
ethyl isopropyl amiloride augmented (rather than blocked) the reduction
in infarct size achieved with preconditioning.33
How can these divergent results be reconciled? Although possible differences in the amiloride analogues used (dimethyl versus ethyl isopropyl amiloride),16 differences between the in vivo and isolated buffer-perfused heart models,11 and/or differences in calcium handling among species34 35 may play a role, a more plausible explanation may lie in the timing of treatment. As discussed previously, we administered intramyocardial injections of DMA 40 minutes before the onset of the test occlusion in an effort to facilitate diffusion and dissipation of the DMA and thereby preclude the well-documented cardioprotection observed when amiloride or its analogues are present during a sustained ischemic insult.22 23 24 25 26 In contrast, in the study by Bugge and Ytrehus, ethyl isopropyl amiloride was added to the perfusate before and throughout the preconditioning stimulus and maintained for 5 minutes into the period of sustained regional ischemia.33 These data suggest an intriguing paradox: prolonged infusion of the amiloride analogue may have abrogated the benefits of preconditioning yet protected the hearts by inhibition of Na+-H+ exchange during sustained occlusion. The concept that an agent or mediator (in this case amiloride) may both initiate protection (when present during sustained occlusion) and have deleterious effects (if administered during the preconditioning stimulus) is not without precedent. For example, a brief increase in intracellular calcium concentration in neurons has been reported to result in a sustained and favorable increase in the excitability of postsynaptic cells,14 36 and formation of oxygen radicals, generally thought to be a deleterious process, has been shown to protect the porcine heart against postischemic dysfunction caused by a brief ischemic insult occurring 1 day later.37 This explanation is speculative, however, and definitive resolution of our findings with those of Bugge and Ytrehus33 awaits further prospective study.
Limitations and Unanswered Questions
Our results imply that brief exposure of myocytes to increased
calcium concentrations protects the canine heart against a subsequent
1-hour sustained period of coronary artery occlusion. Direct
measurement of intracellular calcium levels during CaCl2
infusion and during brief preconditioning ischemia/reperfusion
would clearly strengthen this hypothesis but is beyond the scope of our
in vivo model. The results obtained with DMA treatment further imply
that in the setting of brief preconditioning ischemia, influx
of calcium occurs in large part via Na+-H+
exchange. As with all other studies performed with these agents in
intact heart models, this conclusion is potentially confounded by the
fact that even "selective" analogues of amiloride, including DMA,
can also act on other ion transport systems, protein kinases, and
enzymes.16 Importantly, however, the concentrations of DMA
required to inhibit the Na+ channel,
Na+-Ca2+ exchange, kinase activity, etc, are
10- to 1000-fold higher than the 400 µmol/L DMA briefly
present (before diffusion) at the focal intramyocardial injection
sites.
Although the results from both protocols 1 and 2 are consistent with the concept that calcium plays a role in initiating cardioprotection, the present study (1) does not conclusively prove that the cellular mechanisms responsible for infarct size reduction with CaCl2 infusion are the same as those for infarct size reduction with ischemic preconditioning; (2) does not address the possible relationship between calcium and other known or suspected mediators of preconditioning; and (3) was not designed to identify the second messengers, cellular pathways, or end effectors involved in the ultimate limitation of infarct size with either brief calcium infusion or brief preconditioning ischemia. Although these important ancillary questions remain to be answered, our results nonetheless implicate calcium as an important mediator of infarct size reduction achieved with preconditioning in the canine model.
| Selected Abbreviations and Acronyms |
|---|
|
| Footnotes |
|---|
Received November 5, 1996; revision received February 12, 1997; accepted February 20, 1997.
| References |
|---|
|
|
|---|
2.
Ytrehus K, Liu Y, Downey JM. Preconditioning
protects ischemic rabbit heart by protein kinase C
activation. Am J Physiol. 1994;266:H1145-H1152.
3. Liu Y, Ytrehus K, Downey JM. Evidence that translocation of protein kinase C is a key event during ischemic preconditioning of rabbit myocardium. J Mol Cell Cardiol. 1994;26:661-668.[Medline] [Order article via Infotrieve]
4.
Kitakaze M, Node K, Minamino T, Komamura K, Funaya H,
Shinozaki Y, Chujo M, Mori H, Inoue M, Hori M, Kamada T. Role of
activation of protein kinase C in the infarct size-limiting effect of
ischemic preconditioning through activation of
ecto-5'-nucleotidase. Circulation. 1996;93:781-791.
5.
Przyklenk K, Sussman MA, Simkhovich BZ, Kloner
RA. Does ischemic preconditioning trigger translocation
of protein kinase C in the canine model?
Circulation. 1995;92:1546-1557.
6.
Simkhovich BZ, Przyklenk K, Hale SL, Patterson M,
Kloner RA. Direct evidence that ischemic preconditioning
does not cause protein kinase C translocation in rabbit heart.
Cardiovasc Res. 1996;32:1064-1070.
7. Vogt AM, Htun P, Arras M, Podzuweit T, Schaper W. Intramyocardial infusion of tool drugs for the study of molecular mechanisms in ischemic preconditioning. Basic Res Cardiol. 1996;91:389-400.[Medline] [Order article via Infotrieve]
8.
Przyklenk K, Zhao L, Kloner RA, Elliott GT.
Reduction of infarct size with ischemic preconditioning and
monophosphoryl lipid A: role of adenosine regulating
enzymes? Am J Physiol. 1996;271:H1004-H1014.
9.
Kusuoka H, Koretsune Y, Chacko VP, Weisfeldt ML,
Marban E. Excitation-contraction coupling in
postischemic myocardium: does failure of
activator Ca2+ transients underlie
stunning? Circ Res. 1990;66:1268-1276.
10. Amende I, Bentivegna LA, Zeind AJ, Wenzlaff P, Grossman W, Morgan JP. Intracellular calcium and ventricular function: effects of nisoldipine on global ischemia in the isovolumic, coronary-perfused heart. J Clin Invest. 1992;89:2060-2065.
11.
Hata K, Takasago T, Saeki A, Nishioka T, Goto Y.
Stunned myocardium after rapid correction of acidosis:
increased oxygen cost of contractility and the role of
the Na+-H+ exchange system. Circ
Res. 1994;74:794-805.
12. Opie LH. Role of calcium and other ions in reperfusion injury. Cardiovasc Drugs Ther. 1991;5:237-248.
13. Steenbergen C, Fralix TA, Murphy E. Role of increased cytosolic free calcium concentration in myocardial ischemic injury. Basic Res Cardiol. 1993;88:456-470.[Medline] [Order article via Infotrieve]
14. Marban E. Pathogenic role for calcium in stunning? Cardiovasc Drugs Ther. 1991;5:891-894.[Medline] [Order article via Infotrieve]
15. Pierce GN, Czubryt MP. The contribution of ionic imbalance to ischemia/reperfusion-induced injury. J Mol Cell Cardiol. 1995;27:53-63.[Medline] [Order article via Infotrieve]
16. Kleyman TR, Cragoe EJ. Amiloride and its analogs as tools in the study of ion transport. J Membr Biol. 1988;105:1-21.[Medline] [Order article via Infotrieve]
17.
Ito BR, Tate H, Kobayashi M, Schaper W.
Reversibly injured, postischemic canine
myocardium retains normal contractile reserve.
Circ Res. 1987;61:834-846.
18.
Whittaker P, Kloner RA, Przyklenk K.
Intramyocardial injections and protection against myocardial
ischemia: an attempt to examine the cardioprotective actions of
adenosine. Circulation. 1996;93:2043-2051.
19. Node K, Suzuki S, Tamai N, Hori M. Transient exposure to Ca2+ mediates the infarct-size limiting effect in the canine heart. Circulation. 1994;90(suppl I):I-209. Abstract.
20. Node K, Kitakaze M, Komamura K, Minamino T, Tada M, Inoue M, Hori M, Kamada T. Role of elevation of cellular Ca2+ in activation of ecto-5'-nucleotidase in ischaemic preconditioning. Eur Heart J. 1995;16:26. Abstract.[Medline] [Order article via Infotrieve]
21.
Meldrum DR, Cleveland JC Jr, Sheridan BC, Rowland RT,
Banerjee A, Harken AH. Cardiac preconditioning with calcium:
clinically accessible myocardial protection. J
Thorac Cardiovasc Surg. 1996;112:778-786.
22.
Meng HP, Pierce GN. Protective effects of
5-(N,N-dimethyl)amiloride on
ischemia-reperfusion injury in hearts. Am J
Physiol. 1990;258:H1615-H1619.
23. Smart SC, LoCurto A, Schultz JE, Sagar KB, Warltier DC. Intracoronary amiloride prevents contractile dysfunction of postischemic `stunned' myocardium: role of hemodynamic alterations and inhibition of Na+-H+ exchange and L-type Ca2+ channels. J Am Coll Cardiol. 1995;26:1365-1373.[Abstract]
24. Myers ML, Mathur S, Li GH, Karmazyn M. Sodium-hydrogen exchange inhibitors improve postischaemic recovery of function in the perfused rabbit heart. Cardiovasc Res. 1995;29:209-214.[Medline] [Order article via Infotrieve]
25.
Klein HH, Pich S, Bohle RM, Wollenweber J, Nebendahl
K. Myocardial protection by Na+-H+
exchange inhibition in ischemic, reperfused porcine
hearts. Circulation. 1995;92:912-917.
26. Rohmann S, Weygandt H, Minck KO. Preischaemic as well as postischaemic application of a Na+-H+ exchange inhibitor reduces infarct size in pigs. Cardiovasc Res. 1995;30:945-951.[Medline] [Order article via Infotrieve]
27.
Yao Z, Gross GJ. A comparison of
adenosine-induced cardioprotection and ischemic
preconditioning in dogs. Circulation. 1994;89:1229-1236.
28.
Zucchi R, Ronca-Testoni S, Yu G, Galbani P, Ronca G,
Mariani M. Effect of ischemia and reperfusion on cardiac
ryanodine receptors: sarcoplasmic reticulum Ca2+
channels. Circ Res. 1994;74:271-280.
29.
Zucchi R, Ronca-Testoni S, Yu G, Galbani P, Ronca G,
Mariani M. Postischemic changes in cardiac
sarcoplasmic reticulum Ca2+ channels: a possible mechanism
of ischemic preconditioning. Circ Res. 1995;76:1049-1056.
30. Stokke M, Asknes G, Lande K, Hagelin EM, Bros O. Density of L-type calcium channels in ischaemically preconditioned porcine heart regions. Acta Physiol Scand. 1994;150:425-430.[Medline] [Order article via Infotrieve]
31. Smith GB, Stefenelli T, Wu ST, Wikman-Coffelt J, Parmley WW, Zaugg CP. Rapid adaptation of myocardial calcium homeostasis to short episodes of ischemia in isolated rat hearts. Am Heart J. 1996;131:1106-1112.[Medline] [Order article via Infotrieve]
32. Ramasamy R, Liu H, Anderson S, Lundmark J, Schaefer S. Ischemic preconditioning stimulates sodium and proton transport in isolated rat hearts. J Clin Invest. 1995;96:1464-1472.
33. Bugge E, Ytrehus K. Inhibition of sodium-hydrogen exchange reduces infarct size in the isolated rat heart: a protective additive to ischaemic preconditioning. Cardiovasc Res. 1995;29:269-274.[Medline] [Order article via Infotrieve]
34. Opie LH. Postischemic stunning: the case for calcium as the ultimate culprit. Cardiovasc Drugs Ther. 1991;5:895-900.[Medline] [Order article via Infotrieve]
35.
Sham JSK, Hatem SN, Morad M. Species differences
in the activity of the Na+-Ca2+ exchanger in
mammalian cardiac myocytes. J Physiol. 1995;488:623-631.
36. Regehr WG, Connor JA, Tank DW. Optimal imaging of calcium concentration in hippocampal pyramidal cells during synaptic activation. Nature. 1989;341:533-536.[Medline] [Order article via Infotrieve]
37. Sun SZ, Tang XL, Park SW, Qiu Y, Turrens JF, Bolli R. Evidence for an essential role of reactive oxygen species in the genesis of late preconditioning against myocardial stunning in conscious pigs. J Clin Invest. 1996;97:562-576.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
![]() |
R. A. Bouwman, R. J. P. Musters, B. J. van Beek-Harmsen, J. J. de Lange, R. R. Lamberts, S. A. Loer, and C. Boer Sevoflurane-induced cardioprotection depends on PKC-{alpha} activation via production of reactive oxygen species Br. J. Anaesth., November 1, 2007; 99(5): 639 - 645. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Przyklenk, M. Maynard, C. E. Darling, and P. Whittaker Pretreatment with D-myo-Inositol Trisphosphate Reduces Infarct Size in Rabbit Hearts: Role of Inositol Trisphosphate Receptors and Gap Junctions in Triggering Protection J. Pharmacol. Exp. Ther., September 1, 2005; 314(3): 1386 - 1392. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Barrere-Lemaire, N. Combes, C. Sportouch-Dukhan, S. Richard, J. Nargeot, and C. Piot Morphine mimics the antiapoptotic effect of preconditioning via an Ins(1,4,5)P3 signaling pathway in rat ventricular myocytes Am J Physiol Heart Circ Physiol, January 1, 2005; 288(1): H83 - H88. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. YELLON and J. M. DOWNEY Preconditioning the Myocardium: From Cellular Physiology to Clinical Cardiology Physiol Rev, October 1, 2003; 83(4): 1113 - 1151. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Hattori, H. Otani, T. Uchiyama, H. Imamura, J. Cui, N. Maulik, G. A. Cordis, L. Zhu, and D. K. Das Src tyrosine kinase is the trigger but not the mediator of ischemic preconditioning Am J Physiol Heart Circ Physiol, September 1, 2001; 281(3): H1066 - H1074. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Efstathiou, S. Seraskeris, C. Papakonstantinou, A. Aidonopoulos, and A. Lazou Differential effect of preconditioning on post-ischaemic myocardial performance in the absence of substantial infarction and in extensively infarcted rat hearts Eur. J. Cardiothorac. Surg., April 1, 2001; 19(4): 493 - 499. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Xu, Y. Wang, K. Hirai, A. Ayub, and M. Ashraf Calcium preconditioning inhibits mitochondrial permeability transition and apoptosis Am J Physiol Heart Circ Physiol, February 1, 2001; 280(2): H899 - H908. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Wang, J. Cone, and Y. Liu Dual roles of mitochondrial KATP channels in diazoxide-mediated protection in isolated rabbit hearts Am J Physiol Heart Circ Physiol, January 1, 2001; 280(1): H246 - H255. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Avkiran Protection of the Myocardium During Ischemia and Reperfusion : Na+/H+ Exchange Inhibition Versus Ischemic Preconditioning Circulation, December 21, 1999; 100(25): 2469 - 2472. [Full Text] [PDF] |
||||
![]() |
R. J. Gumina, E. Buerger, C. Eickmeier, J. Moore, J. Daemmgen, and G. J. Gross Inhibition of the Na+/H+ Exchanger Confers Greater Cardioprotection Against 90 Minutes of Myocardial Ischemia Than Ischemic Preconditioning in Dogs Circulation, December 21, 1999; 100(25): 2519 - 2526. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Gysembergh, S. Lemaire, C. Piot, C. Sportouch, S. Richard, R. A. Kloner, and K. Przyklenk Pharmacological manipulation of Ins(1,4,5)P3 signaling mimics preconditioning in rabbit heart Am J Physiol Heart Circ Physiol, December 1, 1999; 277(6): H2458 - H2469. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Karmazyn, X. T. Gan, R. A Humphreys, H. Yoshida, and K. Kusumoto The Myocardial Na+-H+ Exchange : Structure, Regulation, and Its Role in Heart Disease Circ. Res., October 29, 1999; 85(9): 777 - 786. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Wang and M. Ashraf Role of Protein Kinase C in Mitochondrial KATP Channel–Mediated Protection Against Ca2+ Overload Injury in Rat Myocardium Circ. Res., May 28, 1999; 84(10): 1156 - 1165. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Jovanovic, S. Jovanovic, E. Lorenz, and A. Terzic Recombinant Cardiac ATP-Sensitive K+ Channel Subunits Confer Resistance To Chemical Hypoxia-Reoxygenation Injury Circulation, October 13, 1998; 98(15): 1548 - 1555. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Kloner, R. Bolli, E. Marban, L. Reinlib, and E. Braunwald Medical and Cellular Implications of Stunning, Hibernation, and Preconditioning : An NHLBI Workshop Circulation, May 19, 1998; 97(18): 1848 - 1867. [Full Text] [PDF] |
||||
![]() |
Q. Chen, A. K. S. Camara, J. An, M. L. Riess, E. Novalija, and D. F. Stowe Cardiac preconditioning with 4-h, 17{degrees}C ischemia reduces [Ca2+]i load and damage in part via KATP channel opening Am J Physiol Heart Circ Physiol, June 1, 2002; 282(6): H1961 - H1969. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1997 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |